Self-examination low-cost full-field OCT (SELFF-OCT) allows treatment decision for age related macular degeneration (AMD) and diabetic macular edema (DME) with high sensitivity and specificity: clinical pilot study

Helge M Sudkamp; Claus von der Burchard; Moritz Moltmann; Peter Koch; Malte vom Endt; Michael Münst; Christoph Ehlken; Timo Kepp; Dirk Theisen-Kunde; Reginald Birngruber; Gereon Hüttmann

doi:https://doi.org/10.1117/12.2583041

Self-examination low-cost full-field OCT (SELFF-OCT) allows treatment decision for age related macular degeneration (AMD) and diabetic macular edema (DME) with high sensitivity and specificity: clinical pilot study

Helge M Sudkamp, Claus von der Burchard, Moritz Moltmann, Peter Koch, Malte vom Endt, Michael Münst, Christoph Ehlken, Timo Kepp, Dirk Theisen-Kunde, Reginald Birngruber, Gereon Hüttmann

Original language	English
Title of host publication	Ophthalmic Technologies XXXI
Volume	11623
Publication date	2021
Pages	116230Z
DOIs	https://doi.org/10.1117/12.2583041
Publication status	Published - 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

https://doi.org/10.1117/12.2583041

Cite this

Sudkamp, H. M., von der Burchard, C., Moltmann, M., Koch, P., vom Endt, M., Münst, M., Ehlken, C., Kepp, T., Theisen-Kunde, D., Birngruber, R., & Hüttmann, G. (2021). Self-examination low-cost full-field OCT (SELFF-OCT) allows treatment decision for age related macular degeneration (AMD) and diabetic macular edema (DME) with high sensitivity and specificity: clinical pilot study. In Ophthalmic Technologies XXXI (Vol. 11623, pp. 116230Z) https://doi.org/10.1117/12.2583041

@inproceedings{63b1b06b66c24dda9dd4e4c17b006091,

title = "Self-examination low-cost full-field OCT (SELFF-OCT) allows treatment decision for age related macular degeneration (AMD) and diabetic macular edema (DME) with high sensitivity and specificity: clinical pilot study",

author = "Sudkamp, {Helge M} and {von der Burchard}, Claus and Moritz Moltmann and Peter Koch and {vom Endt}, Malte and Michael M{\"u}nst and Christoph Ehlken and Timo Kepp and Dirk Theisen-Kunde and Reginald Birngruber and Gereon H{\"u}ttmann",

year = "2021",

doi = "https://doi.org/10.1117/12.2583041",

language = "English",

volume = "11623",

pages = "116230Z",

booktitle = "Ophthalmic Technologies XXXI",

}

Sudkamp, HM, von der Burchard, C, Moltmann, M, Koch, P, vom Endt, M, Münst, M, Ehlken, C, Kepp, T , Theisen-Kunde, D, Birngruber, R & Hüttmann, G 2021, Self-examination low-cost full-field OCT (SELFF-OCT) allows treatment decision for age related macular degeneration (AMD) and diabetic macular edema (DME) with high sensitivity and specificity: clinical pilot study. in Ophthalmic Technologies XXXI. vol. 11623, pp. 116230Z. https://doi.org/10.1117/12.2583041

Self-examination low-cost full-field OCT (SELFF-OCT) allows treatment decision for age related macular degeneration (AMD) and diabetic macular edema (DME) with high sensitivity and specificity: clinical pilot study. / Sudkamp, Helge M; von der Burchard, Claus; Moltmann, Moritz et al.
Ophthalmic Technologies XXXI. Vol. 11623 2021. p. 116230Z.

Research output: Chapters in Books/Reports/Conference Proceedings › Conference contribution › peer-review

TY - GEN

T1 - Self-examination low-cost full-field OCT (SELFF-OCT) allows treatment decision for age related macular degeneration (AMD) and diabetic macular edema (DME) with high sensitivity and specificity: clinical pilot study

AU - Sudkamp, Helge M

AU - von der Burchard, Claus

AU - Moltmann, Moritz

AU - Koch, Peter

AU - vom Endt, Malte

AU - Münst, Michael

AU - Ehlken, Christoph

AU - Kepp, Timo

AU - Theisen-Kunde, Dirk

AU - Birngruber, Reginald

AU - Hüttmann, Gereon

PY - 2021

Y1 - 2021

U2 - https://doi.org/10.1117/12.2583041

DO - https://doi.org/10.1117/12.2583041

M3 - Conference contribution

VL - 11623

SP - 116230Z

BT - Ophthalmic Technologies XXXI

ER -

Sudkamp HM, von der Burchard C, Moltmann M, Koch P, vom Endt M, Münst M et al. Self-examination low-cost full-field OCT (SELFF-OCT) allows treatment decision for age related macular degeneration (AMD) and diabetic macular edema (DME) with high sensitivity and specificity: clinical pilot study. In Ophthalmic Technologies XXXI. Vol. 11623. 2021. p. 116230Z doi: https://doi.org/10.1117/12.2583041